<DOC>
	<DOCNO>NCT01136525</DOCNO>
	<brief_summary>The purpose study 1 . Compare evaluate single-dose bioavailability study 1000mg Valacyclovir HCl tablet Dr. Reddy 's Valtrex ( R ) ( Valacyclovir Hydrochloride ) CAPLETS 1 gram GlaxoSmithkline , healthy , adult human subject fast condition . 2. monitor adverse event ensure safety subject .</brief_summary>
	<brief_title>Bioavailability Study Valacyclovir HCl Tablets , 1000 mg Dr. Reddy 's Under Fasting Conditions</brief_title>
	<detailed_description>An open label , balance , randomize , two-treatment , two-sequence two-period , single-dose , crossover comparative bioavailability study 1000 mg Valacyclovir Hydrochloride Tablets Dr. Reddy 's Laboratories Ltd. , India valtrex ( R ) ( Valacyclovir Hydrochloride ) CAPLETS 1 gram GlaxoSmithkline healthy , adult human subject fast condition</detailed_description>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>The subject select study participation , base follow criterion : 1 . Human subject age 18 45 year ( include ) . 2 . Subjects ' weight within normal range accord normal value Body Mass Index ( 18.5 24.9 kg/m2 ) minimum 50 kg weight . 3 . Subjects normal health determine personal medical history , clinical examination laboratory examination within clinically acceptable normal range . 4 . Subjects normal 12lead electrocardiogram ( ECG ) . 5 . Subjects normal chest XRay ( PIA view ) . 6 . Have negative urine screen drug abuse ( include amphetamine , barbiturate , benzodiazepine , marijuana , cocaine , morphine ) . 7 . Have negative alcohol breath test . 8 . Subjects willing adhere protocol requirement provide write informed consent . The subject exclude study , base follow criterion : 1 . Hypersensitivity Valacyclovir Hydrochloride relate drug . 2 . History presence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , endocrine , immunological , dermatological , neurological psychiatric disease disorder . 3 . History presence significant alcoholism drug abuse past one year . 4 . History presence significant smoking ( 10 cigarette beedi ' s/day ) . 5 . History presence significant asthma , urticaria allergic reaction . 6 . History presence significant gastric and/or duodenal ulceration . 7 . History presence significant thyroid disease , adrenal dysfunction , organic intracranial lesion pituitary tumour . 8 . History presence cancer . 9 . Difficulty donate blood . 10 . Difficulty swallow solid like tablet capsule . 11 . Systolic blood pressure le 100 mm Hg 140 mm Hg . 12 . Diastolic blood pressure le 60 mm Hg 90 mm Hg . 13 . Pulse rate le 50/minute 100/minute . 14 . Oral temperature le 95°F 98.6°F . 15 . Respiratory rate le 12/minute 20/minute 16 . Subjects use prescription medication , within 14 day period 01 dose OTC medication within 14 day period 01 dosing . 17 . Major illness 3 month screen . 18 . Participation drug research study within past 3 month . 19 . Donation blood past 3 month screen . 20 . Subjects consume xanthinecontaining product ( include caffeine , theobromines , etc . ) within 48 hour prior period 01 dosing . 21 . Subjects consume food beverage contain grapefruit pomelo within 14 day prior period 01 dosing . 22 . Subjects use drug substance know strong inhibitor CYP enzyme ( formerly know cytochrome P450 enzyme ) within 28 day prior first dose . 23 . Subjects use drug substance know strong inducer CYP enzyme ( formerly know cytochrome P450 enzyme ) within 28 day prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Crossover</keyword>
	<keyword>Valacyclovir Hydrochloride</keyword>
</DOC>